# Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients

> **NCT01579812** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 90 (actual)

## Conditions studied

- Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

## Interventions

- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT01579812
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2017-06
- **Final completion:** 2017-07
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2018-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01579812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01579812, "Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01579812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*